OncoMatch

OncoMatch/Clinical Trials/NCT05987644

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Is NCT05987644 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Alectinib for lung cancer.

Phase 1/2RecruitingJoshua PalmerNCT05987644Data as of May 2026

Treatment: AlectinibThis study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: ALK rearrangement

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: investigational drug

Treatment with any investigational drug within 28 days prior to registration

Lab requirements

Blood counts

Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.

Kidney function

Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.

Liver function

Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.

Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Stanford University · Stanford, California
  • University of Colorado Cancer Center · Aurora, Colorado
  • Ohio State University Comprehensive Cancer Center · Columbus, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify